Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5284897
Max Phase: Preclinical
Molecular Formula: C17H10FN3O2
Molecular Weight: 307.28
Associated Items:
ID: ALA5284897
Max Phase: Preclinical
Molecular Formula: C17H10FN3O2
Molecular Weight: 307.28
Associated Items:
Canonical SMILES: O=c1[nH]n2c(=O)c3ccccc3nc2/c1=C/c1ccc(F)cc1
Standard InChI: InChI=1S/C17H10FN3O2/c18-11-7-5-10(6-8-11)9-13-15-19-14-4-2-1-3-12(14)17(23)21(15)20-16(13)22/h1-9H,(H,20,22)/b13-9-
Standard InChI Key: DCMYHQMCRQKYSM-LCYFTJDESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 307.28 | Molecular Weight (Monoisotopic): 307.0757 | AlogP: 1.22 | #Rotatable Bonds: 1 |
Polar Surface Area: 67.23 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 7.43 | CX Basic pKa: 2.96 | CX LogP: 2.50 | CX LogD: 2.25 |
Aromatic Rings: 4 | Heavy Atoms: 23 | QED Weighted: 0.57 | Np Likeness Score: -1.06 |
1. Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K.. (2022) Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors., 13 (5.0): [PMID:35685617] [10.1039/d1md00280e] |
Source(1):